EyeTechCare raises nearly $13 million (€10 million) for a clinical trial of its EyeOP1 ultrasound device for treating glaucoma, aiming for a nod from U.S. regulators.
EyeTechCare said it landed nearly $13 million in its 3rd round of funding, aiming to use the cash to fund a clinical trial of its EyeOP1 ultrasound glaucoma treatment, which has been on the market in Europe since
Rillieux-la-Pape, France-based EyeTechCare said the backers include private investor Dr. Bernard Chauvin and prior investors Omnes Capital and France's SHAM insurance company.
The EyeOP1 device won CE Mark approval in the European Union in May 2011, according to a press release, and hit doctors' shelves there in late 2012. The device uses high-intensity focused ultrasound in an "ultrasound circular cyclo-coagulation" procedure to partially destroy the cilia that generate intraocular pressure, according to the release.